Evaluation of the MoA of Allosteric Modulators and Its Application to Drug Discovery using Back-Scattering Interferometry

Speakers_JeffRegeanDr. Jeff Reagan, Scientific Director, Department of Metabolic Disorders, Amgen, Inc.
Scot Weinberger, Director, Co-Founder, Executive Vice President of Molecular Sensing Inc.

Presented on November 13, 2015 at a CHI Web Symposia

Symposium Overview

This symposium describes the unique strengths of Back-Scattering Interferometry (BSI) for understanding the mechanism of action of allosteric drug targets in metabolic disease. The course commences with a brief review of BSI technology and principles and proceeds by reviewing a specific case study for a metabolic disease target. The strengths, advantages, and convenience of the BSI technique are emphasized and contrasted with radio-ligand assays. Other target examples are also presented including GPCR membrane preparations.

Learning Objectives
  • – Understand Back-Scattering Interferometry (BSI) technology and assay development
  • – Learn how BSI advances allosteric drug research for a specific metabolic disease target
  • – Learn how BSI advances allosteric drug research for GPCR targets in membrane preparations
  • – Learn of BSI’s distinguishing advantages compared to radiolabel techniques classically applied in allostery studies
Speaker Bios
Scot Weinberger
Director, Co-Founder, Executive Vice President, Molecular Sensing Inc.

Scot has over 20 years of experience in life science instrumentation development before founding Molecular Sensing. Most recently, he founded GenNext Technologies, a company dedicated to advancing education in translational medicine. Scot was Director of Research Proteomics for Ciphergen Biosystems, where he led R&D in mass spectrometry and molecular interaction technology. Earlier in his career he was VP of R&D at Linear Scientific, which he helped sell to Hewlett-Packard and Spectra-Physics and subsequently held key R&D positions at both companies. Scot’s academic training was in cellular biology with a BS degree and post-graduate medical school training from the University of Nevada, Reno. Scot holds 30 different US and international patents in the areas of life science research.

Jeff Reagan
Scientific Director, Department of Metabolic Disorders, Amgen, Inc.

Jeff Reagan received his PhD in chemistry from Yale University in 1986. He pursued postdoctoral studies at the Yale University School of Medicine in the Department of Neurobiology studying the molecular pharmacology of olfaction. He joined Sandoz/Novartis in 1989 working in the area of G protein coupled receptors. In 1998 he joined Affmax where he extended his work on the molecular pharmacology of GPCRs. In 2001 he joined Tularik (acquired by Amgen in 2004) and has worked in the area of diabetes, nephrology and cardiovascular disease with a specific emphasis in systolic heart failure. His key area of interest is the molecular pharmacology and mathematical modeling of allosteric modulators.



All fields are required.

First Name

Last Name


Work Email